Dose-optimization using exposure response analysis in AFM24 (in monotherapy and with atezolizumab) in patients with advanced/metastatic non-small cell lung cancer

Tecentriq (atezolizumab) - Roche

AFM24 - Affimed

https://www.abstractsonline.com/pp8/#!/20273/presentation/10506

Anthony El-Khoueiry1; Omar Saavedra2; Juanita Lopez3; Hye Ryun Kim4; Daniela Morales-Espinosa5; Daniel Schütz5; Andre Overesch5; Andreas Harstrick5; Kerstin Pietzko5

Mar 26, 2025